NANOBIOTIX to Announce First Quarter 2022 Financial Results on

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 4, 2022--Regulatory News:

NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer,

today announced that it will report its financial results for the first quarter of 2022 ending March 31, 2022, on Wednesday, May 18, 2022, after the close of the US market.

The announcement will be followed by a conference call and live audio webcast on Thursday, May 19, 2022, at 8:00 AM EDT / 2:00 CET, prior to the opening of the US market. During the call, Laurent Levy, chief executive officer, and Bart Van

Rhijn, chief financial officer, will briefly review the Company's first quarter results and provide an update on operational activities before taking questions from analysts and investors. Investors are invited to email their questions in

advance to investors@nanobiotix.com.

Details for the call are as follows:

In the 10 minutes prior to call start time, call the appropriate Dial-In number listed below.

Enter the Event Plus Passcode stated below and leavy any information requested after the tone. You will join automatically to the conference.

Dial-In Information:

Live (US/Canada): +16467413167

Live France: +33170700781

Live (International): +44 (0) 2071 928338

Event Plus Passcode: 7795306

A live webcast of the call may be accessed by visiting: https://edge.media-server.com/mmc/p/tvhmyyuz

A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website.

NBTXR3 is a novel, potentially first-in-class oncology product, composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. The product candidate's

physics-based mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering an adaptive immune response and long-term anti-cancer memory. Given the

MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly, with immune checkpoint inhibitors.

NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) as the primary development pathway. The company-sponsored phase I dose escalation and dose expansion study has produced favorable safety data and

early signs of efficacy. In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of

patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy.

Nanobiotix has also prioritized an Immuno-Oncology development program-beginning with a Company sponsored phase I clinical study, evaluating NBTXR3 activated by radiotherapy in combination with anti-PD-1 checkpoint inhibitors for patients

with locoregional recurrent or recurrent/metastatic HNSCC and for patients with lung or liver metastases from any primary cancer eligible for anti-PD-1 therapy, either na ve or resistant to prior PD-1 (either primary or secondary as per SITC

Given the Company's focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in strategic collaborations to expand development of the product candidate in parallel with its priority development pathways.

Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several phase I and phase II studies to evaluate NBTXR3 across

tumor types and therapeutic combinations. In 2021, the Company entered into an additional strategic collaboration agreement with LianBio to support its global phase III study in Asia along with four future registrational studies.

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for

humanity. The company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain and Germany.

Nanobiotix has been listed on the regulated market of Euronext in Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The

company's resources are primarily devoted to the development of its lead product candidate- NBTXR3 -which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients

with soft tissue sarcoma under the brand name Hensify .

This press release contains certain "forward-looking" statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such

as "at this time," "anticipate," "believe," "expect," "intend," "on track," "plan," "scheduled," and "will," or the negative of these and similar expressions. These forward-looking statements, which are based on our management's current

expectations and assumptions and on information currently available to management, include statements about the timing and progress of clinical trials, the timing of our presentation of data, the results of our preclinical and clinical

studies and their potential implications. Such forward-looking statements are made in light of information currently available to us and based on assumptions that Nanobiotix considers to be reasonable. However, these forward-looking

statements are subject to numerous risks and uncertainties, including with respect to the risk that subsequent studies and ongoing or future clinical trials may not generate favorable data notwithstanding positive early clinical results and

the risks associated with the evolving nature of the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to it. Furthermore, many other important factors, including those described

in our Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the SEC) on April 8, 2022 under "Item 3.D. Risk Factors" and those set forth in the universal registration document of Nanobiotix filed with the French

Financial Markets Authority (Autorit des March s Financiers - the AMF) on April 8, 2022, each as updated in our Half-Year Financial Report filed with the AMF and the SEC on September 8, 2021 (a copy of which is available on

www.nanobiotix.com), as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or

implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in

the forward-looking statements, even if new information becomes available in the future.

Communications Department

Investor Relations Department

SVP, Investor Relations

FR - Ulysse Communication

Pierre-Louis Germain

+ 33 (0) 6 64 79 97 51